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ABSTRACT
CYP450-dependent interactions and toxicological consequences of hypoglycemic and antihypertensive 
drugs used in treatment of children with metabolic syndrome (MS) remained unclear. Our aim was to carry 
out a complex estimation of metabolic syndrome and losartan mediated changes in CYP3A, CYP2C, CYP2E1 
mRNA expression, corresponding marker enzymes activities, liver antioxidant system and lipid peroxidation 
parameters of adult and pubertal rats. Wistar albino male rats of two age categories (young animals of 21 
days age (50–70 g) and adults (160–180 g) were divided into 6 groups (6 animals in each): 1 – Control 1 
(intact young rats); 2 – Control 2 (intact adult rats); 3 –young rats with MS; 4 – adult rats with MS; 5 – young 
rats with MS+losartan; 6 – adult rats with MS+ losartan. The metabolic syndrome model was induced 
by full replacement of drinking water with 20% fructose solution (200 g/l). After 60 days of MS modeling, 
investigation of rat liver CYP3A, CYP2C, CYP2E1 mRNA expression, their marker enzymes activities, lipid 
peroxidation parameters were carried out. Losartan administration caused increase of CYP3A, CYP2C 
and CYP2E1 mRNA expression rates in both age groups. Marker enzymes, glutathione transferase and 
reductase rates were normalized only in adult rats. In group of pubertal animals losartan administration led 
to CYP3A and CYP2C marker enzymes activities normalization. Liver reduced glutathione contents remained 
decreased in both age groups. Thus, losartan demonstrates some age-dependent effectiveness towards 
normalization of CYP450 isoforms expression rates, p-nitrophenol hydroxylase, erythromycin-N-demethylase 
and diclofenac hydroxylase activities, but not glutathione system and lipid peroxidation rates. 
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Introduction
Metabolic syndrome (MS) belongs to pathological 
states that could affect CYP450 activity. It is modern 
medicine’s actual problem caused by an unhealthy 
lifestyle. Last decades MS is increasingly spreading 
among children and adolescents [1]. An emerging 
epidemic of pediatric hypertension is paralleled an 
increasing prevalence of childhood obesity. Elevated 
blood pressure during childhood and adolescence is 
associated with end-organ damage [1]. 
Already available clinical data highlight that pediatric 
drug dosing, safety and efficacy cannot simply be 
extrapolated from adult clinical trials [1]. Particularly in-
teresting is the study of the joint effect of metabolic syn-
drome and drugs designed to correct its symptoms. In 
this case, it is possible to identify possible additional 
modifying factors for drugs biotransformation with this 
pathology. Unfortunately, the information dedicated to 
this issue is extremely limited [2, 3]. There are no data 
on CYP450-dependent interactions of hypoglycemic 
and antihypertensive drugs used in the treatment of MS 
in children and adolescents and no detailed analysis of 
their use toxicological consequences. Our preliminary 
results indicate the presence of certain dependencies 
of CYP3A, CYP2C and CYP2E1 levels on age at MS [4]. 
Losartan was the first among angiotensin receptor 
blockers approved for pediatric hypertension by the 
United States FDA in 2004 following completion of the 
required clinical trials [1]. According to data obtained 
in vitro losartan is metabolized mainly via CYP3A and 
CYP2C isoforms of CYP450 [5, 6]. But there are no 
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data on its effects on CYP450 isoforms in children and 
adolescents with MS.
The aim of this work was to study the joint ef-
fects of MS and losartan on hepatic CYP3A, CYP2C, 
CYP2E1 mRNA expression, their marker enzymes, liver 
antioxidant system and lipid peroxidation of adult and 
pubertal rats with MS. 
Materials and methods
A total of 36 Wistar albino male rats of two age cat-
egories (young animals of 21 days age (50-70g) and 
adults (160–180g)) were used in the study. They were 
kept under a controlled temperature (from 22 °C to 
24 °C), relative humidity of 40 % to 70 %, lighting (12 h 
light-dark cycle), and on a standard pellet feed diet 
(“Phoenix” Ltd., Ukraine). The study was performed in 
accordance with the recommendations of the European 
Convention for the Protection of Vertebrate Animals 
used for Experimental and other Scientific Purposes 
and approved by the Institutional Animal Care and Use 
Committee. The model of metabolic syndrome was 
reproduced according to the protocol of Abdulla et al. 
[7]. Young and adult animals were divided into 6 groups 
(6 animals in each group): 1 — Control 1 (intact young 
rats), 2 — Control 2 (intact adults), 3 — MS3 (young rats 
with MS), 4 — MS4 (adult rats with MS), 5 — MS3+lo-
sartan (young rats with MS and losartan (4,43 mg/kg 
of body weight, per os, 60 days)), 6 — MS4+ losartan 
(adult rats with MS and losartan treatment). MS was 
induced by full replacement of drinking water with 20% 
fructose solution (200g/l). 
Crystalline D-fructose > 99% (Khimlaborreactiv, 
Ukraine, series 072000897834, batch XW 130105) was 
used in experiments. 20% fructose was prepared daily 
and given every day for two months ad libitum. In our ex-
periments, losartan (potassium losartan, manufactured 
by LLC “KUSUM PHARM”, Sumy, Ukraine) was used. 
After 60 days of 20%, fructose solution consumption 
and losartan treatment rats were sacrificed under mild 
ether anaesthesia by decapitation. 
Post mitochondrial and microsomal fractions of 
livers were obtained by the method of Kamath et al. 
[8], and aliquots were kept frozen at -70°C until needed. 
We investigated changes of rat orthologs of hu-
man cytochromes P-450: CYP2E1, CYP3A2 instead 
of CYP3A4 [9] and CYP2C23 instead of CYP2C9 and 
CYP2C19 [10]. p-Nitrophenol (PNP) hydroxylase 
activity (a selective enzyme marker for CYP2E1) was 
determined in a microsomal fraction of liver accord-
ing to the method of Koop et al. [11]. Erythromycin 
N-demethylase activity (a selective enzyme marker for 
CYP3A) was determined in liver microsomal fraction 
according to the method of Wang et al. [12], diclofenac 
hydroxylase activity (a selective enzyme marker for 
CYP2C) — according to the method of Necrasova et 
al. [13]. Glutathione-S-transferase activity was deter-
mined in liver post mitochondrial fraction according to 
the method of Habig et al. [14], glutathione reductase 
activity - in microsomes in accordance with „Current 
Protocols in Toxicology” [15], reduced glutathione 
and proteins SH-groups contents — in liver homog-
enates by method of Sedlak with Ellman’s reagent 
[16]. Protein contents were determined with Total 
Protein Kit, Micro Lowry, Onishi & Barr Modification 
(Sigma-Aldrich, Ink., USA).
The rats’ livers were used for investigation of cy-
tochrome P-450 isoforms mRNA expression rates by 
method of reversed transcriptase polymerase chain 
reaction (rPCR). Isolation of total mRNA was carried 
out with TRI-Reagent (Sigma, USA). Synthesis of 
cDNA was carried out with reagents and protocol of 
Fermentas (Germany). rPCR reaction mixture con-
tents, specific primers for CYP2E1 gene amplification 
(forward 5’-CTTCGGGCCAGTGTTCAC-3’ and reverse 
5’- CCCATATCTCAGAGTTGTGC-3’), as well as amplifi-
cation protocol were chosen according to Lankford et al. 
[17]. rPCR reaction mixture, amplification protocol and 
following specific primers – forward 5’-TACTACAAGG-
GCTTAGGGAG-3’ and reverse 5’- CTTGCCTGTCTCCG-
CCTCTT-3’ were used for CYP3A2 gene amplification 
according to Jager et al. [9]. rPCR reaction mixture, 
amplification protocol and following specific primers 
— forward 5’-GATGCTGTCTTCCGTCATGC-3’ and 
reverse 5’- GTAATAGGCTTGATGTCAAG-3’ were used 
for CYP2C23 gene amplification according to Imaoka et 
al. [10]. rPCR with primers of b-actin (sense 5’–GCTC-
GTCGTCGACAACGGCTC–3’ and antisense 5’–CAAA-
CATGAT CTGGGTCATCTTCT–3’) was carried out for 
internal control. All primers were synthesized by «Me-
tabion» (Germany). Thermocycler MyCycler (BioRaD, 
USA) was used for amplification. Electrophoresis of PCR 
products (CYP2E1-744 b.p., CYP2C23-252 b.p., CY-
P3A2 — 349 b.p. and b-actin-353 b.p.) was carried out 
in 2% agarose gels (80 V; 1.5 h). After electrophoresis 
gels were stained with ethidium bromide and visualized 
under a UV transilluminator (BIORAD, USA). Electro-
phoresis data analysis was carried out with Quantity 
One Software (USA). 
The levels of lipid peroxidation (LPO) in liver micro-
somes were investigated as the rates of NADPH-depen-
dent thiobarbituric acid reactive substances (TBARS) 
formation [18].
Results 
CYP2E1 mRNA expression comparative study in the 
livers of pubertal and adult rats with MS and losartan 
administration demonstrated pronounced changes at 
both age groups of rats (Fig. 1).
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Figure 1. CYP2E1 mRNA content in the liver of pubertal and adult rats with MS and losartan administration: A, C 
— representative electrophoregrams of CYP2E1 (744 b.p) and reference-gene b-actin (353 b.p.) RT-PCR products; B, 
D — average rate of CYP2E1 mRNA expression in the liver (n = 6, Mr - DNA marker, signal intensity of b-actin was taken 
as 100%); *P < 0.05 in comparison with control; **P < 0.05 in comparison with MS
CYP2E1 mRNA expression was increased at a group 
of pubertal animals with MS (1.8 folds compared with 
the control) and the group of pubertal animals with 
MS and losartan administration (more than 2.0 folds 
compared with the control). Losartan, administered to 
adult animals with MS, resulted in 2–2.5 folds increase 
in expression of the CYP2E1 gene. 
MS caused statistically significant growth of 
CYP3A2 mRNA expression at a group of pubertal ani-
mals (Fig. 2). Changes of CYP3A2 gene expression in 
adult animals with MS were not significantly different 
from control. Results on CYP3A2 mRNA expression 
investigation in the livers of pubertal and adult rats with 
MS and losartan administration demonstrated more 
pronounced changes at groups of young rats. Losartan, 
administered to pubertal animals with MS, increased the 
level of CYP3A2 mRNA expression. In adult animals, 
losartan did not cause statistically significant changes 
in the level of CYP3A2 mRNA expression. 
In the case of CYP2C23, we detected a reduction 
of mRNA expression levels in livers of both age groups 
with MS as compared with controls: pubertal animals 
-1.4 folds, adults — 1.6 folds (Fig. 3). Losartan adminis-
tration allowed normalizing CYP2C23 mRNA expression 
rates only in the group of pubertal animals. In the group 
of adult animals, such losartan effect was absent. 
We investigated the activity of PNP-hydroxylase in 
liver microsomes of adult and pubertal rats with MS and 
losartan administration. Statistically significant growth 
of PNP- hydroxylase activity with MS was detected 
both at pubertal (1.6 fold) and adult (1.38 fold) animals 
groups (Tab. 1). 
Study of pubertal rats’ microsomal PNP-hydroxylase 
activity with MS and losartan administration also gener-
ally matched data on CYP2E1 gene expression. In this 
group rate of PNP-hydroxylase activity was increased 
by 1.7 fold as compared with the control. Changes in 
PNP-hydroxylase activity in the liver microsomal fraction 
of adult animals with MS and losartal administration 
were opposite: normalization to the control levels. 
The investigation of erythromycin-N-demethylase 
activity showed MS opposite (by nature) effects in 
groups of pubertal (3 fold reduction) and adult animals 
(46% increase). But losartan administration caused 
normalization of erythromycin-N-demethylase activities 
with MS irrespective of age.
Investigation of diclofenac-hydroxylase activity rates 
(Tab. 1) demonstrated its reduction with MS in rats of 
both age groups (more pronounced in adults). As in the 
case of erythromycin-N-demethylase losartan adminis-
tration led to normalization of diclofenac-hydroxylase 
activity rate in both age groups.
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Figure 2. CYP3A2 mRNA content in the liver of pubertal and adult rats with MS and losartan administration: 
A, C — representative electrophoregrams of CYP3A2 (349 b.p) and reference-gene b-actin (353 b.p.) RT-PCR products; 
B, D — average rate of CYP3A2 mRNA expression in liver (n = 6, Mr — DNA marker, signal intensity of b-actin was taken as 100%)
*P < 0.05 in comparison with control
Figure 3. CYP2C23 mRNA content in the liver of pubertal and adult rats with MS and losartan administration: A, C 
— representative electrophoregrams of CYP2C23 (252 b.p) and reference-gene b-actin (353 b.p.) RT-PCR products; B, 
D — average rate of CYP2C23 mRNA expression in liver (n = 6, Mr — DNA marker, signal intensity of b-actin was taken as 
100%); *P < 0.05 in comparison with control; **P < 0.05 in comparison with MS
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Table 1. Activities of PNP-hydroxylase, erythromycin-N-demethylase and diclofenac hydroxylase in liver microsomal fraction of 
pubertal and adult rats (M ± SEM, n = 6)
Groups Activity of PNP- hydroxylase, 
nmoles×min-1 × mg of 
protein-1
Activity of erythromycin-N-
demethylase, nmoles×min-1 
× mg of protein-1
Activity of diclofenac 
hydroxylase, nmoles×min-1  
× mg of protein-1
Control 1 0.46 ± 0.021 0.96 ± 0.17 552.0 ± 19.1
MS3 0.74± 0.051* 0.32 ± 0.09* 380.2 ± 13.8*
MS3 + losartan 0,77 ± 0,065 * 1,04 ± 0,38 568,8 ± 161,0
Control 2 0.45 ± 0.018 0.22 ± 0.02 403.6 ± 14.8
MS4 0.62 ± 0.055** 0.32 ± 0.03** 140.8 ± 14.3**
MS4 + losartan 0,44 ± 0,040 0,20 ± 0,02 576,7 ± 93,5#
 *P < 0.05 in comparison with control 1; **P < 0.05 in comparison with control 2; 
# P < 0.05 in comparison with MS4
Table 2. Contents of reduced glutathione and glutathione transferase and reductase activities in liver of pubertal and 
adult rats with MS (M ± SEM, n = 6)
Groups Activity of glutathione 
reductase, nmoles×min-1  
× mg of protein-1
Activity of glutathione 
transferase, µmoles×min-1  
× mg of protein-1
Contents of glutathione,
µmoles×g of tissue-1 
Control 1 109.8 ± 4.6 1.35 ± 0.09 2.28 ± 0.33
MS3 89.4 ± 5.9 * 1.08 ± 0.05 * 1.30 ± 0.15*
MS3 + losartan 88,6 ± 6,4 * 1,04 ± 0,080 * 1,25 ± 0,11*
Control 2 115.0 ± 5.5 1.25 ± 0.09 2.58 ± 0.27
MS4 114.0 ± 5.0 1.12 ± 0.06 1.48 ± 0.18**
MS4 + losartan 110,8 ± 4,2 1,04 ± 0,059 1,80 ± 0,18**
*P < 0.05 in comparison with control 1; **P < 0.05 in comparison with control 2
In our experiments, glutathione-S-reductase 
(-18.5%), glutathione transferase (-20%) activities and 
reduced glutathione contents (-43%) were significantly 
decreased in pubertal rats with MS (Tab. 2). Losartan 
administration also caused a profound decrease in lev-
els of glutathione-S-reductase, glutathione transferase 
and glutathione contents. In adults losartan administra-
tion with MS led only to glutathione contents decrease.
Simultaneously with changes in glutathione metab-
olism, LPO processes in rats liver cells were intensified 
(Tab. 3). This was indicated by the increased rates of 
NADPH-dependent thiobarbituric acid reactive sub-
stances production both in groups with MS and losartan 
administration with MS irrespective of age. 
Discussion
It is absolutely obvious that to increase therapy’s 
efficiency and safety it is necessary to have accurate 
CYP450 isoforms profile information in each individual 
case. It allows to establish the potential interaction of 
drugs, including competition for specific isoforms, the 
individual variability associated with high polymorphism 
of these isoforms, and different isoenzymes possible 
induction. Some of the pathologies including MS, 
obesity and diabetes could additionally modify 
profiles of CYP450 isoforms thus changing drugs ef-
fects. Unfortunately, such data are limited to several 
studies in adults, and specifics of metabolic processes 
in children and adolescents are generally not taken into 
account by researchers and clinicians [2, 3]. In view 
of the above, we have identified expression profiles of 
three isozyme CYP450 in the liver of pubertal rats and 
adult animals with MS and losartan administration. 
Our results on the enhancement of CYP2E1 gene 
expression with MS are in agreement with other authors 
data, which showed an increase in CYP2E1 activity in 
laboratory animals with obesity, which is one of the 
main constituents of MS [19, 20]. Administration of 
losartan to pubertal and adult rats with MS did not 
lead to normalization of the CYP2E1 expression level 
in the liver. Regarding the p-nitrophenol hydroxylase 
(CYP2E1 marker enzyme), its activity increased in the 
group of pubertal rats both with MS and losartan ad-
ministration with MS. This is consistent with the above 
findings of the CYP2E1 gene expression study. Howev-
er, we have not registered changes in the p-nitrophenol 
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Table 3. NADPH-dependent LPO in rat liver microsomal fractions with MS and losartan administration (M ± SEM; n = 6;)
Groups NADPH-dependent LPO, nmoles×min-1 × mg of protein-1
Pubertal rats Adult rats
Control 0,078 ± 0,007 0,105 ± 0,02
Metabolic syndrome 0,170 ± 0,04* 0,167 ± 0,02*
Metabolic syndrome +losartan 0,133 ± 0,016* 0,164 ± 0,015*
*P < 0.05 in comparison with control 
hydroxylase activity in the microsomal fraction of adult 
rat liver. In this case, CYP2E1 expression intensification 
was not accompanied by the stimulation of the corre-
sponding enzyme activity, as noted by other research-
ers in relation to various isoforms of CYP450 [21, 22]. 
Such age-dependent differences in losartan effects 
with MS might be due to changes in number, affinity, 
density, and/or subtypes of angiotensin I and II recep-
tors [23–25].
The metabolism of losartan in the liver of rats also 
involves CYP2C and CYP3A isoforms [26–28]. The 
MS greatly affects the expression of the CYP3A2 gene 
(CYP3A4 orthologue) in the liver of pubertal rats, 
increasing its level by 30% compared with the control 
group. Regarding the erythromycin-N-demethylase 
(CYP3A2 marker enzyme), its activity decreased in 
the group of pubertal rats with MS. Interestingly, other 
authors also showed a decrease in the clearance of 
CYP3A4 cytochrome substrates in obese patients 
compared to normal [21]. It could be evidence of this 
isoenzyme’s activity decrease with this pathology. In our 
opinion, synchronous loss of CYP3A4 activity and its 
gene expression increasing might be in this case due to 
post-translational glycosylation. This process includes, 
besides the modification of enzyme’s activity, changes 
of its localization in certain cellular compartments and 
start of proteasomal degradation processes [29]. Our 
assumption is confirmed by the data of enzymatic 
kinetics study of non-glycosylated and glycosylated 
isomyforms of CYP450 aromatase [30].
Losartan increased the expression level of CY-
P3A2 mRNA in pubertal rats, but the erythromycin-N-de-
methylase activity remained at the control level. This, ob-
viously, could be explained by the complex interrelations 
of this drug simultaneous actions as a substrate and an 
inducer on the erythromycin-N-demethylase [31, 32]. 
Losartan affinity to CYP3A2 could be also changed with 
MS [33]. In adult rats with MS, administration of losartan 
resulted in the maintenance of both CYP3A2 expression 
and enzymatic activity at the control levels.
We demonstrated the reduced expression of CY-
P2C23 mRNA (ortholog CYP2C9 and CYP2C19) in the 
liver of pubertal rats with MS compared to controls. This 
can be entirely expected taking into account the partic-
ular sensitivity of CYP1A2, CYP2C19, and CYP3A4 iso-
forms expression regulatory systems with liver patho-
logical changes [34]. Although it should be noted that 
their activity may vary selectively, depending on the type 
of pathology [34]. Losartan administration under these 
conditions led to the normalization of this indicator: 
expression of the CYP2C23 gene in the liver of pubertal 
rats was at the same level as in the control group. The 
activity of diclofenac hydroxylase (CYP2C23 marker 
enzyme) also remained at the control level. Losartan, 
administered to adult rats, revealed increased both the 
level of CYP2C mRNA expression and the activity of 
diclofenac hydroxylase.
It should be noted (summarizing the results of 
CYP450 isoforms expression study), that significant 
variability in the expression rates of CYP3A and CYP2C 
genes is present in pubertal rats compared with adults 
with MS. Also, must be stressed the fact that losartan, 
administered to adult and pubertal rats, has different 
effects on CYP3A and CYP2C mRNA expressions regu-
lation. While this drug did not correct CYP2C expression 
rate in the liver of adult rats with MS, it provided this 
indicator normalization in pubertal rats. Similarly, with 
respect to CYP3A, losartan had a much stronger effect 
on gene expression in pubertal rats.
Among profound changes in CYP450 isoforms 
expression rates, treated pathological processes, 
additionally, could significantly change rates of other 
biotransformation processes, which play the important 
role on drugs effects realization [19]. During the drugs 
biotransformation, not only biologically active and 
inactive metabolites are produced, but also cytotoxic 
reactive intermediates may appear [19]. The reactive 
metabolites formed as a result of the metabolism in the 
first phase of detoxification can be neutralized through 
reactions of the second phase, most a significant of 
which is the conjugation with the glutathione with the 
participation of S-transferase. In previous experiments, 
we showed that with metabolic syndrome at the same 
time as changes in certain cytochrome P-450 isoforms 
expression levels, deviations in the functioning of the 
glutathione system occur [4]. They differed significantly 
depending on the age of the experimental animals and 
were more profound in pubertal rats with MS. 
Modulations of CYP450 system caused by MS and 
losartan administration are accompanied by the reduc-
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tion of antioxidant protection, which creates conditions 
for oxidative stress development. Our previous investi-
gations of MS age-dependent effects showed more pro-
found changes in reduced glutathione contents, as well 
as glutathione-S-transferase and reductase activities at 
pubertal animals, while at adults — only glutathione 
contents decreased [4]. Losartan administration didn’t 
cause any normalizing effects on glutathione-system 
at both age groups. But in groups of pubertal animals 
negative effects of MS and losartan administration on 
glutathione-S-transferase and glutathione reductase 
were more pronounced. Our data on glutathione sys-
tem changes are in accordance with other authors’ 
results obtained in experiments in vivo [35–37]. 
The analysis of our own data and other authors’ 
results allows suggesting that the antioxidant and 
anti-inflammatory effect of losartan in liver tissues [37] 
obviously is realized by the cytokine-mediated mech-
anism without involving glutathione system.
MS (according to our previous data) caused oxida-
tive stress and stimulated lipid peroxidation [4]. These 
processes play important roles in MS development [38]. 
Losartan administration weakly suppresses levels of 
MS-induced lipid peroxidation. More pronounced this 
effect was in a group of pubertal animals. Our results 
are consistent with other researchers data [39]. These 
results could be an additional confirmation of our above-
mentioned suppositions on mechanisms of losartan 
antioxidant and anti-inflammatory effects in liver tissues.
Conclusion
Thus, losartan effectiveness towards normalization 
of CYP450 isoforms expression rates, p-nitrophenol hy-
droxylase, erythromycin-N-demethylase and diclofenac 
hydroxylase activities (but not glutathione system and 
lipid peroxidation rates) depends on the age of exper-
imental animals. The lack of information on the age 
characteristics of losartan effects on the CYP450 and 
glutathione systems states with MS makes this data 
particularly important. The obtained results are another 
confirmation of the need to optimize and individualize 
MS therapy, taking into account the age of the patient. 
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